Literature DB >> 29376465

Burden of gout in the Nordic region, 1990-2015: findings from the Global Burden of Disease Study 2015.

A A Kiadaliri1, T Uhlig2, M Englund1,3.   

Abstract

OBJECTIVE: To explore the burden of gout in the Nordic region, with a population around 27 million in 2015 distributed across six countries.
METHOD: We used the findings of the 2015 Global Burden of Diseases study to report prevalence and disability associated with gout in the Nordic region.
RESULTS: From 1990 to 2015, the number of prevalent gout cases rose by 30% to 252 967 [95% uncertainty interval (UI) 223 478‒287 288] in the Nordic region. In 2015, gout contributed to 7982 (95% UI 5431‒10 800) years lived with disability (YLDs) in the region, an increase of 29% (95% UI 24‒35%) from 1990. While the crude YLD rate of gout increased by 12.9% (95% UI 7.8‒18.1%) between 1990 and 2015, the age-standardized YLD rate remained stable. Gout was ranked as the 63rd leading cause of total YLDs in the region in 2015, with the highest rank in men aged 55-59 years (38th leading cause of YLDs). The corresponding rank at the global level was 94. Of 195 countries studied, four Nordic countries [Greenland (2nd), Iceland (12th), Finland (14th), and Sweden (15th)] were among the top 15 countries with the highest age-standardized YLD rate of gout.
CONCLUSION: The burden of gout is rising in the Nordic region. Gout's contribution to the total burden of diseases in the region is more significant than the global average. Expected increases in gout burden owing to population growth and ageing call for stronger preventive and therapeutic strategies for gout management in Nordic countries.

Entities:  

Mesh:

Year:  2018        PMID: 29376465     DOI: 10.1080/03009742.2017.1405461

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  7 in total

1.  Cause-Specific Mortality in Patients with Gout in the United States Veteran's Health Administration: A Matched Cohort Study.

Authors:  Lindsay N Helget; Bryant R England; Punyasha Roul; Harlan Sayles; Alison D Petro; Tuhina Neogi; James R O'Dell; Ted R Mikuls
Journal:  Arthritis Care Res (Hoboken)       Date:  2022-03-16       Impact factor: 5.178

2.  Temporal trends and regional disparity in rheumatoid arthritis and gout hospitalizations in Sweden, 1998-2015.

Authors:  Aliasghar A Kiadaliri; Martin Englund
Journal:  Clin Rheumatol       Date:  2018-01-22       Impact factor: 2.980

3.  Romidepsin suppresses monosodium urate crystal-induced cytokine production through upregulation of suppressor of cytokine signaling 1 expression.

Authors:  M C P Cleophas; T O Crişan; V Klück; N Hoogerbrugge; R T Netea-Maier; C A Dinarello; M G Netea; L A B Joosten
Journal:  Arthritis Res Ther       Date:  2019-02-06       Impact factor: 5.156

4.  Cichorium intybus L. Extract Suppresses Experimental Gout by Inhibiting the NF-κB and NLRP3 Signaling Pathways.

Authors:  Yu Wang; Zhijian Lin; Bing Zhang; Zhuoxi Jiang; Fanfan Guo; Ting Yang
Journal:  Int J Mol Sci       Date:  2019-10-04       Impact factor: 5.923

5.  12-month results from the real-life observational treat-to-target and tight-control therapy NOR-Gout study: achievements of the urate target levels and predictors of obtaining this target.

Authors:  Till Uhlig; Lars F Karoliussen; Joseph Sexton; Tove Borgen; Espen A Haavardsholm; Tore K Kvien; Hilde Berner Hammer
Journal:  RMD Open       Date:  2021-03

6.  Prevalence of Patients Receiving Urate-Lowering Medicine in Greenland and Denmark: A Cross-Sectional Case-Control Study.

Authors:  Sidsel Dan Hull; Marianne Welzel Andersen; Jessica Bengtsson; Nils Skovgaard; Marie Balslev Backe; Michael Lynge Pedersen
Journal:  Int J Environ Res Public Health       Date:  2022-06-13       Impact factor: 4.614

7.  Educational inequalities in all-cause and cause-specific mortality among people with gout: a register-based matched cohort study in southern Sweden.

Authors:  Ali Kiadaliri; Margarita Moreno-Betancur; Aleksandra Turkiewicz; Martin Englund
Journal:  Int J Equity Health       Date:  2019-10-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.